Prescribing information

 

       

On this page you'll find access to more information on ENERZAIR® BREEZHALER® (indacaterol acetate/glycopyrronium bromide/mometasone furoate inhalation powder) and are provided with some materials that you can share with your patients. 

Your Choice with KISQALI logo

THE USE OF THE ENERZAIR® BREEZHALER® DEVICE

This guide helps familiarise HCPs and patients on the use of the ENERZAIR® BREEZHALER® device

 

View

 

Screenshot of Patient Information Booklet

PATIENT INFORMATION BOOKLET ON THE ENERZAIR® DEVICE AND SENSOR

This booklet has been designed to help guide patients on the use of the ENERZAIR® BREEZHALER® device and Sensor

To order copies of this material, please contact a Novartis representative by clicking here

 

Preview

 

""

ENERZAIR® BREEZHALER® STEP-BY-STEP INSTRUCTION GUIDE FOR PATIENTS

This step-by-step guide has been designed to show patients how to use their ENERZAIR® BREEZHALER® inhaler correctly, to ensure they receive the correct dosage

To order copies of this material, please contact a Novartis representative by clicking here

 

Preview

 

PODCAST

Our podcast series focuses on the unmet needs in asthma – Why do patients remain uncontrolled?1–6

Learn more

 

Indication: ENERZAIR® BREEZHALER® is indicated as a maintenance treatment for asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid, who experienced one or more asthma exacerbations in the previous year.7

References

  1. Buhl R, et al. Respir Med 2020;162:105859.
  2. WHO. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma. Date accessed: January 2021.
  3. Kerstjens HA, et al. N Engl J Med 2012;367:1198–207.
  4. Kerstjens HA, et al. Respir Med 2016;117:198–206.
  5. Azzi E et al. NPJ Prim Care Respir Med 2017;27:29.
  6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2014. Available from: https://ginasthma.org/wp-content/uploads/2019/01/2014-GINA.pdf. Date accessed: January 2021.
  7. ENERZAIR® BREEZHALER® Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | February 2021 | 103408
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]